{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:15:03Z","timestamp":1766182503054,"version":"3.41.0"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>This study aims to assess the cost-effectiveness of adebrelimab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) from the Chinese medical perspective.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We have designed a partitioned survival model. The model integrates clinical information pertaining to overall survival, progression-free survival, adverse events and cost data. Our primary measure of outcome in this model is quality-adjusted life years (QALY) and the incremental cost-effectiveness ratio (ICER). The model adopted a willingness to pay (WTP) threshold of $40,343.68 per QALY. To account for uncertainty in the model parameters, we conducted sensitivity analyses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The total expenditure for the adebrelimab group was $79,549.34, compared to $6,436.80 for the chemotherapy group. The adebrelimab cohort achieved an incremental gain of 1.25 QALY, resulting in an additional cost of $73,112.54. Consequently, the ICER for the adebrelimab group was determined to be $58,490.03 per QALY, surpassing the WTP threshold of $40,343.68 in China. The sensitivity analyses demonstrated the robustness of the findings across various scenarios.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This cost-effectiveness analysis indicates that adebrelimab plus chemotherapy as a first-line treatment for ES-SCLC was not cost-effective in China with a WTP of $40,343.68.Reducing the cost of adebrelimab promises to improve the cost-effectiveness of this treatment regimen.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0325171","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T17:36:08Z","timestamp":1749836168000},"page":"e0325171","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of adebrelimab in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-3221","authenticated-orcid":true,"given":"Zhiwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huide","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"10","key":"pone.0325171.ref001","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.trecan.2024.07.008","article-title":"Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity","volume":"10","author":"E Redin","year":"2024","journal-title":"Trends Cancer"},{"issue":"24","key":"pone.0325171.ref002","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.3390\/cancers14246132","article-title":"A novel therapeutic target for small-cell lung cancer: tumor-associated repair-like schwann cells","volume":"14","author":"S Cao","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0325171.ref003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"CM Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0325171.ref004","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.semcancer.2022.05.004","article-title":"Small cell lung cancer: novel treatments beyond immunotherapy","volume":"86","author":"J-J Meijer","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"22","key":"pone.0325171.ref005","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1002\/cncr.34977","article-title":"Advancing immunotherapy in small cell lung cancer","volume":"129","author":"JW Carlisle","year":"2023","journal-title":"Cancer"},{"issue":"6","key":"pone.0325171.ref006","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"J Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"pone.0325171.ref007","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Y Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"6","key":"pone.0325171.ref008","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40258-024-00900-5","article-title":"Use of cost-effectiveness thresholds in healthcare public policy: progress and challenges","volume":"22","author":"O Espinosa","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"pone.0325171.ref009","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1080\/13696998.2023.2272536","article-title":"Economic burden of advanced lung cancer patients treated by gefitinib alone and combined with chemotherapy in two regions of China","volume":"26","author":"K Yang","year":"2023","journal-title":"J Med Econ"},{"key":"pone.0325171.ref010","doi-asserted-by":"crossref","first-page":"699781","DOI":"10.3389\/fonc.2021.699781","article-title":"First-line chemo-immunotherapy for extensive-stage small-cell lung cancer: a united states-based cost-effectiveness analysis","volume":"11","author":"Q Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"pone.0325171.ref011","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/13696998.2020.1772797","article-title":"Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics","volume":"23","author":"RL Mendoza","year":"2020","journal-title":"J Med Econ"},{"key":"pone.0325171.ref012","year":"2024"},{"key":"pone.0325171.ref013","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"P Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"pone.0325171.ref014","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling","volume":"37","author":"C Williams","year":"2017","journal-title":"Med Decis Making"},{"issue":"2","key":"pone.0325171.ref015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40273-013-0123-9","article-title":"Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial","volume":"32","author":"V Diaby","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"pone.0325171.ref016","doi-asserted-by":"crossref","first-page":"1259574","DOI":"10.3389\/fonc.2023.1259574","article-title":"Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer","volume":"13","author":"Z Zheng","year":"2024","journal-title":"Front Oncol"},{"key":"pone.0325171.ref017","unstructured":"Central People\u2019s Government of the People\u2019s Republic of China. The State Council Office of the People\u2019s Republic of China held a press conference on the \u201cReport on the Nutrition and Chronic Disease Status of Chinese Residents (2020)\u201d. [cited 2025 Jan 20]. Available from: https:\/\/www.gov.cn\/xinwen\/2020-12\/23\/content_5572785.htm"},{"key":"pone.0325171.ref018","author":"YaoZH","year":"2025"},{"issue":"9","key":"pone.0325171.ref019","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/14737167.2023.2281606","article-title":"Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China","volume":"24","author":"S Kang","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"pone.0325171.ref020","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s11096-024-01802-1","article-title":"Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China","volume":"46","author":"W Lang","year":"2024","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"pone.0325171.ref021","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14737167.2024.2378986","article-title":"Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis","volume":"24","author":"Z Zheng","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"pone.0325171.ref022","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: An international study","volume":"13","author":"B Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"pone.0325171.ref023","volume-title":"The China Guidelines for Phaumacoeconomic Evaluation (2020 English Edition)","author":"G Liu","year":"2020"},{"issue":"16","key":"pone.0325171.ref024","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037836","article-title":"Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer","volume":"103","author":"M Meng","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pone.0325171.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0320189","article-title":"Tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a cost-effectiveness analysis","volume":"20","author":"Z Zheng","year":"2025","journal-title":"PLoS One"},{"key":"pone.0325171.ref026","doi-asserted-by":"crossref","first-page":"102795","DOI":"10.1016\/j.eclinm.2024.102795","article-title":"Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial","volume":"75","author":"D Chen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"pone.0325171.ref027","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2022.09.222","article-title":"Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II to III NSCLCs: an open-label, multicenter, phase 1b trial","volume":"18","author":"W Yan","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"9","key":"pone.0325171.ref028","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1377\/hlthaff.2023.01344","article-title":"Consumer out-of-pocket drug prices grew faster than prices faced by insurers after accounting for rebates, 2007-20","volume":"43","author":"J Mallatt","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"11","key":"pone.0325171.ref029","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jval.2023.06.020","article-title":"Cancer drug prices in the united states: efficacy, innovation, clinical trial evidence, and epidemiology","volume":"26","author":"DT Michaeli","year":"2023","journal-title":"Value Health"},{"issue":"10","key":"pone.0325171.ref030","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/jjco\/hyae094","article-title":"High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group)","volume":"54","author":"K Watanabe","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"pone.0325171.ref031","doi-asserted-by":"crossref","DOI":"10.1097\/BRS.0000000000000576","article-title":"Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses","volume":"39","author":"PD Angevine","year":"2014","journal-title":"Spine (Phila Pa 1976)"},{"issue":"7","key":"pone.0325171.ref032","article-title":"Improving access to medicines and beyond: the national volume-based procurement policy in China","volume":"8","author":"Z Zhu","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"3","key":"pone.0325171.ref033","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054346","article-title":"Impact of \u201c4+7\u201d volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China","volume":"12","author":"J Wang","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0325171.ref034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004332","article-title":"Price negotiation and pricing of anticancer drugs in China: an observational study","volume":"21","author":"J Zhou","year":"2024","journal-title":"PLoS Med"},{"issue":"4","key":"pone.0325171.ref035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077090","article-title":"Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China","volume":"14","author":"Y Long","year":"2024","journal-title":"BMJ Open"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T17:36:15Z","timestamp":1749836175000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0325171"}},"subtitle":[],"editor":[{"given":"Abdene Weya","family":"Kaso","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":35,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0325171","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}